Biotech RadarJobs updated

COMPANY

Lantern Pharma

HQ: Dallas, TX source · lanternpharma.com ↗ · Southwest

Clinical Phase 2

Keywords: oncology adenocarcinoma Adenocarcinoma of Lung Non-Small-Cell Lung Carcinoma GBM TNBC - Triple-Negative Breast Cancer NSCLC Pancreatic Adenocarcinoma DDR Gene Mutation Relapsed or Refractory Lymphomas LP-300 LP-184 LP-284

Location: Dallas, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

$17.2MRaised (2 yrs)3Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering — Registered direct: $8M (up to, as announced), announced Sep 30, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering — Registered direct: $9.25M (up to, as announced), announced May 14, 2026. Source: SEC filing. source ↗ · Form D filed May 21, 2026 SEC Form D ↗
  3. Trial start Phase 1/Phase 2: Study of LP-184 in Patients With Advanced Solid Tumors source ↗
  4. Trial start Phase 2: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma source ↗
  5. Trial start Phase 1: Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $17.2M. Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPhase 2RecruitingMar 1, 20232026-12 (estimated)
NCT05933265Study of LP-184 in Patients With Advanced Solid TumorsPhase 1/Phase 2Active, not recruitingJun 9, 2023Jul 28, 2026 (estimated)
NCT06132503Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsPhase 1RecruitingJan 3, 2023Nov 30, 2028 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback